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Aducanumab for Alzheimer’s disease?
Patients and families need hope, not false hope
Sebastian Walsh, 1 Richard Merrick, 1 Richard Milne, 2 Carol Brayne1
The US licensing of Biogen’s aducanumab as “the
first ever disease modifying drug for Alzheimer’s
disease” was hailed as a major advance by many.
However, in response to the decision, three members
of the Food and Drug Administration’s expert
independent advisory committee,whichvotedalmost
unanimously against approval, resigned, with
Harvard professor of medicine Aaron Kesselheim
describing it as “probably the worst drug approval
decision in recent US history.”1 Given that existing
treatments for Alzheimer’s disease have only
marginal benefit at best,2 what does aducanumab’s
controversial approval in the US mean for patients,
clinicians, and researchers?
Amyloid protein clumps in the brain (plaques) are a
neuropathological feature ofAlzheimer’s disease and
widely assumed to trigger a cascade of changes that
cause cognitive decline. Aducanumab is a
monoclonal antibody that removes amyloidplaques.3
The central controversy is whether the amyloid
clearance protects patients from cognitive and
functional decline.
This should have been answered by two identically
designed (pre-approval) phase III trials, but it wasn’t.
Both were stopped after preplanned early analyses
on data up to December 2018 determined that the
trials were “futile” (<20% chance of overall trial
returning a positive finding).4 However, Biogen,
which funded the trial, continued collecting data
until the announcementof termination inMarch 2019.
Reanalysis of data up to March 2019 confirmed the
drug’s ineffectiveness in one study, but the other
suggested cognitive benefit.
Biogen submitted its reanalysis to the FDA, and
together they ran several retrospective analyses to
explore the discrepancy between the two trials.4
Despite extensive evidence of ineffectiveness of other
anti-amyloid agents,5 6 the new analyses focused on
explaining why one of the trials had returned a
negative result, rather than exploring why the other
one had not. None of these analyses found anything
morepersuasive thana chance result thatwouldhave
“regressed to the mean” (averaged out as ineffective)
had the trials continued to completion.4 7
The FDA concluded that there were “residual
uncertainties regarding clinical benefit.”8 Instead of
recommending a new phase III trial, it granted a
licenceunder its “accelerated approval”pathway for
drugs that “may provide meaningful therapeutic
benefit” based on a surrogate endpoint “that is
reasonably likely to predict a clinical benefit.”8 This
decision was remarkable because the only evidence
that amyloid removal (a surrogate) slows cognitive
decline (clinical benefit) comes from their
retrospective analysis of the single trial and ignores
abundant evidence of no benefit,5 6 including the
negative, identically designed trial.
Years of uncertainty
Attempting reassurance, the FDA committed Biogen
to a nine year post-approval confirmatory study. So
we may not know until at least 2030 whether
aducanumab slows cognitive decline, during which
time the drug will be sold for use at a cost of $56 000
(£41 000; €43 000) per person each year.1 Moreover,
phase IV post-approval trials may not be able to
establish efficacy or lack thereof since, unlike
pre-approval trials, they are designed primarily to
identify rare side effects and real world effectiveness.
We have been here before: the dementia drugs
donepezil, galantamine, rivastigmine, and
memantine were defunded in France in 2018 after
over a decade of use because there was no evidence
of clinically meaningful benefit.2
A big challenge for US clinicians and patients is the
FDAdecision to approve aducanumab for anypatient
with Alzheimer’s disease,9 despite Biogen’s trials
including only those with early disease.
What will happen outside the US? In 2018 the
European Medicines Agency (including the UK)
updated its guidelines on clinical trials for
Alzheimer’s disease10 to emphasise the need for trials
to show cognitive and functional benefits rather than
focusing solely on surrogate endpoints such as
amyloidplaques.Approval of aducanumab inEurope
would be inconsistent with this guidance and is
therefore unlikely.
Even if approved, bodies such as the UK National
Institute for Health and Care Excellence would
struggle to reconcile uncertain clinical efficacy with
the cost of treatment: aswell asmonthly intravenous
infusions for an indefinite period, patients require
repeated magnetic resonance imaging to monitor for
side effects; 35% of patients in the trials experienced
brain oedema and 19% micro-haemorrhages at the
recommended dose.4
US approval of aducanumab has consequences for
trials of other potential Alzheimer’s treatments.
Researchers will now have to decide whether to use
aducanumab or placebo as a control intervention.
Use of placebo controls will be particularly
challenging in the US when an FDA approved drug
is already available.
This evolving story may ultimately damage public
trust in regulatory and licensing institutions. This is
deeply undesirable at any time, but particularly in
the middle of a pandemic when public trust in
lifesaving vaccines is so imperative.
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People with Alzheimer’s disease and their families need hope, not
false hope. Aducanumab’s approval on a technicality could
undermine regulatory standards designed to protect against false
hope and “set a dangerous precedent.”11 12
Thedebate about the role of amyloid inAlzheimer’s disease remains
intensely controversial. Aducanumab’s approval does little to
resolve this controversy, while creating unhelpful uncertainties for
patients, clinicians, and researchers. Some see aducanumab as
proof of concept for the amyloid cascade theory, justifying decades
of unsuccessful research costing billions of pounds and exposing
thousands of participants to the side effects of experimental
treatments. Others fear it will simply encourage futile investment
in anti-amyloid therapies, diverting funds away from effective
preventionmeasures suchas improvingphysical activity or reducing
hypertension,13 and better support after diagnosis.
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